

CURRICULUM VITAE

Name Dr. Deepak Dabkara
Qualification M.D (Internal Medicine)
DM (Medical Oncology)

Date of birth 09 April 1977

Citizenship Indian

E-mail deepakdabkara@yahoo.com

Educational Qualification

Degree	Year	Institute	University
DM (Medical Oncology, 3 year fellowship program)	2007-09	All India Institute of Medical Sciences (AIIMS), New Delhi	AIIMS, New Delhi, India
MD (Internal Medicine)	2001-04	MGM Medical college, Indore	DAVV, Indore , MP, India
MBBS	1995-2000	MGM Medical college, Indore	DAVV , Indore, MP, India

MCI Registration : MP - 4306

Professional Experience

- Working as **Senior Consultant and HOD Medical Oncology** at BALCO Medical Center, Raipur, Chattisgarh from 2 Aug 2023 to 4 July 2024
- Worked as Senior Consultant Medical Oncology, CHL Hospital 114, Indore, MP from 13 Dec 2021 to March 2023
- October 2011 – Nov 2021 : Worked as a **Senior Consultant in Medical Oncology (Solid tumor unit), Tata Medical Center, Kolkata, India. Special interest in male genitourinary, breast & lung cancer**
- **Observership for 1 month in Taussig Cancer Centre, Cleveland Clinic Ohio, USA from 16 Sept to 14 Oct 2017**
- Feb 2011 – Sept 2011 : Worked as a **Consultant in Bone Marrow Transplant, Advanced Centre for Treatment, Research & Education in Cancer, ACTREC, Tata Memorial Hospital, Mumbai, India**
- Jan 2010- Dec 2010 : Worked as a **Consultant, Dept of Medical Oncology, Tata Memorial Hospital, Mumbai, India**
- Jan 2007 – Dec 2009 : Worked as a **Senior Resident (D.M)** in the Department of Medical Oncology, Institute Rotary Cancer Hospital, **All India Institute of Medical Sciences, New Delhi, India**
- Jan 2006 – Dec 2006 : Worked as a **Senior Resident (non acad)** in the Department of Medical Oncology, Institute Rotary Cancer Hospital, **All India Institute of Medical Sciences , New Delhi, India**
- Oct 2004 – Nov 2005 : Worked as a **Senior Resident (D.N.B.)** in the Department of Medical Oncology, **Jaslok Hospital, Mumbai, India** under guidance of Dr S.H. Advani

Publications/ Presentations

- Review article : Recent advances in first line management of metastatic RCC – **Deepak Dabkara, Bivas Biswas - IJMPO Feb 2022**
- Review article : Cancer treatment induced bone loss and role of denosumab in non metastatic carcinoma prostate – **Deepak Dabkara , IJMPO, 2021, 42, 240-246**
- Review article : How I treat metastatic hormone sensitive prostate cancer – **Deepak Dabkara,**

Debopriya Mondal et al, IJMPO, 2021 , 42 (01) 100-107

- How we treat genitourinary malignancies in COVID 19 pandemic. **Deepak Dabkara**, Sandip Ganguly, Joydip Ghosh, Biwas Biswas, July 2020, Asian pacific journal of cancer care, supplement 1 (147-152)
- Metronomic therapy in metastatic CRPC, experience from tertiary cancer center, **Deepak Dabkara**, S Ganguly, B Biswas, J Ghosh , Indian journal of cancer 2018, vol 55
- Clinical experience of tyrosine kinase inhibitors in metastatic renal cell carcinoma: results from a cancer center in Eastern India **D. Dabkara**, B Biswas, A.D. Dwary, I. Ghosh, S. Mukherjee, S. Gupta, I. Mallick, P. Mondal.. Annals of Oncology 26 (Supplement 9): ix71–ix79, 2015
- Perspective of oncology patients during COVID 19 pandemic : A prospective observational study from India. Joydeep Ghosh, Sandip Ganguly, Debapriya Mondal, Prashant Pandey, **Deepak Dabkara**, Bivas Biswas JCO Global Oncology, June 2017, 2020
- Managing brain lesions in gynecological cancers : A case series Subhashree Rout, Shweta Rai, **Deepak Dabkara**, Joydeep Ghosh, Sept 2020, Indian J of gynecologic oncology 18 (3)
- A novel oxaliplatin desensitization protocol safe and effective. Shauryo Ghosh, Sandip Ganguly, Joydip Ghosh, **Deepak Dabkara**, IJMPO June 2020
- Next generation sequencing in lung cancer : An initial experience from India, Pragya Gupta, K Saha, Mayur Parihar, Divya Midha , **Deepak Dabkara** et al, Current Problems in Cancer, march 2020
- Ado Trastuzumab Emtansine : Monoclonal drug conjugate in her 2 positive breast cancer , Sandip Ganguly, Joydip Ghosh, **Deepak Dabkara**, Bivas Biswas IJMPO June 2020
- How we treat lung cancer in COVID 19 pandemic in India, Bivas Biswas, Sandip Ganguly, Joydip Ghosh, **Deepak Dabkara**, IJMPO May 2020
- Ado Trastuzumab : Drug review : Sandip Ganguly, Joydip Ghosh, **Deepak Dabkara** , IJMPO June 2020
- Real world experience of treatment and outcome in ALK positive lung cancer, a multicentric study from India, Amol Patel, Ullas Batra, KT Prasad, **Deepak Dabkara** et al, Current problems in cancer, March 2020, 44(3)
- Immune checkpoint inhibitors in lung cancer : A metacentric experience from India : S Kumar, S Joga, U Batra, B Biswas, **Deepak Dabkara**, Current problem in India, March 2020
- Utility and safety of maintenance chemotherapy in NSCLC across various performance status PS categories , a real world experience, KT Prasad, V Muthu, Bivas Biswas, **Deepak Dabkara** et al, Current problems in Cancer, March 2020
- Clinicopathological features and clinical outcome of small cell lung cancer , a single

institutional experience from India : Sandip Ganguly, Bivas Biswas, Joydip Ghosh, Sumit M, Divya M, Sayantika B, **Deepak Dabkara**, Lung India, Feb 2020

- Systemic treatment of GE cancer during SARS COV2, J Ghosh, B Biswas, S Ganguly, **Dabkara D**, S Priyanka, A Patel, A Batra, P Mehta, IJMPO ,2 (41)
- Clinical and pathological features and outcome of clear cell carcinoma of ovary, A tertiary cancer center data, J Ghosh, A Ghosh, Divya Midha, J Bhaumik, B Chakroborty, A Roy, **Deepak Dabkara**, B Biswas, Dec 2019, Indian journal of gynaec oncology
- Metastatic muscle metastasis in a case of ca GB with TP 53 mutation : A rare case report , J Ghosh, S Ganguly, **D Dabkara**, B Biswas, SAJC Oct 2019
- A phase I/II study of stereotactic hypofractionated weekly radiotherapy in prostate cancer , I Mallick, Moses A, P Roy , S chakroborty, **D Dabkara**, R Basu, S Chatterjee, S Gupta, Sept 2019, Clinical Oncology
- Radical radiotherapy or CRT in NSCLC, analysis of patient profile, treatment approaches and outcome of 213 patients at a tertiary cancer center, RK Shrimali, Chandan N, A saha, A Das, S Prasad, S Ahata, **D Dabkara**, R Basu, I Mallick, Robin T, Dec 2018, Indian journal of cancer
- Lung cancer in adolescents and young adults : Single center experience from eastern India, B Biswas, S Ganguly, **D Dabkara**, J Ghosh , Nov 2018, Annals of oncology, 29 (supplement 9)
- Outcome and prognostic factors in metastatic ALK positive lung cancer, single center experience : Oct 2018, Journal of thoracic oncology
- Metastatic gastric cancer, real world scenario from a developing country , S Ganguly, J Ghosh, **D Dabkara**, July 2018, South Asian J of cancer
- Pattern of recurrences in TNBC , an Indian tertiary cancer center data (Poster, ASCO 2018), May 2018 (JCO, supplement)
- Seminoma testis , treatment outcome from a tertiary cancer center – Accepted for publication in NMJI
- Non small cell lung cancer metastasis to unusual sites : A retrospective case series. Sandip Ganguly, Joydeep Ghosh, Aneesha Gehani, Archisman Basu, Meheli Chatterjee, **Deepak Dabkara**, Bivas Biswas, CRST Jan -March 2021
- Outcome of NSGCT : report from a tertiary cancer center in eastern India : Bivas Biswas, **Deepak Dabkara**, Sandip Ganguly et al, ecancer 2021 , 15, 1204
- Adrenal metastasis in an older patient with seminoma, Archisman Basu, **Deepak Dabkara**, CRST, jan 2021
- Seminomatous and non seminomatous mediastinal germ cell tumors : A real world analysis from two tertiary cancer centers in India , ASCO 2021

- PDL1 expression and its correlation with outcome in non metastatic TNBC , Joydip Ghosh, Meheli Chatterjee, Sandip Ganguly **Deepak Dabkara**, *ecancer* , 2021
- Metastatic gastric cancer : Real world scenario from a developing country : Sandip Ganguly, Bivas Biswas, Joydeep Ghosh, Deepak Dabkara: *South Asian J of Cancer* 2018 : 171-4
- Cytoreductive nephrectomy in metastatic renal cell carcinoma in the era of targeted therapy: Scientifically relevant or natural selection. Bivas Biswas, **Deepak Dabkara**, Sandip Ganguly, Prasad Eswaran, Joydeep Ghosh, *JCO* Feb 2017
- Bevacizumab in advanced angiosarcoma; What is the reality? Biswas B, **Dabkara D** *JCO* March 1, 2016, Vol 34, No7,764
- Survival of patients with metastatic breast cancer with or without locoregional therapy. Bivas B, **Dabkara D**, Ganguly S. *The Lancet Oncology*, vol 16, No 16e586-e587,dec 2015.
- Outcome following a moderately hypofractionated adjuvant radiation schedule for breast cancer in an unscreened non caucasian population. Chatterjee S, Arunsingh M, Agrawal S, **Dabkara D**, Mahata A, Arun I, Shrimali RK, Achari R, Mallick I, Ahmed R. *Clin Oncol (R Coll Radiol)*. 2016 Oct;28(10):e165-72.
- In – transit metastasis from malignant melanoma, Biswas B, **Dabkara D**, Ganguly S. *Natl Med J India*. 2016 (In press)
- Long term survivor of HIV associated plasmablastic lymphoma. Sharma A, TVSVGK Tilak, Lodha R, Sharma MC, **Dabkara D**, *IJMPO* Apr-Jun,2013.
- Acute promyelocytic leukemia : An experience from a tertiary care center in North India : Bajpai J, Sharma A, Kumar L, **Dabkara D**, Raina V, Kochupillai V, Kumar R. *Indian J Cancer*. 2011 Jul-Sep; 48(3):316-22.
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma, **Dabkara D**, Bajpai J. *Indian Journal of Medical and Paediatric Oncology*, Vol. 29 No 3, 2008.
- Metastatic ovarian carcinoma, **Deepak Dabkara**, Atul Sharma, *Indian Journal of Medical and Paediatric Oncology*, Vol. 30 Suppl. 1, 2009
- High incidence of early metabolic syndrome in germ cell tumor: Report from a tertiary cancer center in India; Bivas Biswas, **Deepak Dabkara**, Sandip Ganguly, Amit Dutt Dwary, Indranil Ghosh, Saugata Sen, Sumit Mukhopadhyay, Satyadip Mukherjee, Sujoy Gupta, Indranil Mallick, Pradip Mondal and Monish De, *J Clin Oncol*. Vol 34, No 2_suppl 2016: 488
- Crizotinib toxicity, dose adjustments and initial response: a single centre experience. M. Arun Singh, RK. Shrimali, **D. Dabkara**, B Biswas D. Midha, M. Parihar, G.Mukherjee, D. Mishra, S. Chatterjee. *Lung Cancer* 91, Suppl. 1 (2016) S1–S71.
- Early Clinical experience of Sandwich Therapy in Endometrial Cancer. S. Ganguly, R. Achari, **D. Dabkara**, B Biswas, J.Bhaumik. *J Carcinog* 2016, 15:2

- EGFR and EML4-Alk testing for non-small cell lung cancer patients – a single centre experience S. Chatterjee, N. Arora, M. Parihar, D. Midha, G. Mukherjee, **D. Dabkara**, B Biswas, D. Mishra, R. Shrimali.. Lung Cancer 91, Suppl. 1 (2016) S1–S71
- Adjuvant chemotherapy for upper tract urothelial carcinoma : is there sufficient evidence ? Vol 35, No 18, JCO June 2017 Bivas Biswas, Sandip ganguly, Joydeep ghosh, Prasad E, **Deepak Dabkara**
- Patterns of recurrence in triple negative breast cancer patients: an Indian Tertiary Care Center data : Joydeep Ghosh, sanjit agarwal, Sandip ganguly, **Deepak Dabkara**, Bivas Biswas, Shibarati nandi, Journal of Clinical Oncology, 2018
- Outcome and prognostic factors in ALK +ve metastatic adenocarcinoma of lung : Single center experience from eastern India : B Biswas, D Dabkara, s Ganguly, R Shrimali, J Ghosh, **D Dabkara**, D Midha, G Mukherjee, M parihar, D Mishra, N Arora ,
- Clinicopathological characteristics, and treatment outcome in small cell lung cancer, a single institutional experience : S ganguly B Biswas, J Ghosh, R Shrimali, J Ghosh, **D Dabkara**, D Midha, G Mukherjee, , Au, M Chatterjee, A hassan, S das
- Metastatic colorectal cancer : Real life experience from an indian tertiary cancer center, Vinod sharma, Atul sharma, Vinod raina, **Deepak Dabkara** etal, BMC Cancer, 2021 , 21 : 630
- Imaging recommendations for diagnosis, staging and treatment of esophageal cancer, Nivedita Chakrabarty , Abhishek Mahajan , Prachi Patil, Manoranjan Chowhan, Naveen Munmmudi, Devayani Niyogi, **Deepak Dabkara**, Suryaveer Singh, Ajaykumar Singh, Sanjana Devarmani, Varun Singh Dhull, Kumar Prabhash. IJMPO 2023 (44), 02
- Mediastinal sampling by EBUS in cancer patients: Is it always metastatic? Tiyas Sen, Bivas Biswas, Deepak Dabkara, Sandip Ganguly , Indian journal of chest diseases and allied sciences, **May 2023**
- Early metabolic syndrome in testicular GCT, a prospective study from India. Prashant Pandey, Deepak Dabkara, Joydip Ghosh, Reena Nair, Bivas Biswas, **June 2022**, Journal of Clinical Oncology 40(16_suppl):e17010-e17010
- Expert survey on management of prostate cancer in India, Real world insight into practice pattern. **May 2022**, IJC, 59
- Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India, **March 2022**, Indian Journal of Cancer 59(Supplement):S1-S10

- Sequencing of therapies in management of advanced prostate cancer in India, A Delphi based consensus, **Jan 2022**, Oncology and therapy 10 (1)
- Clinicopathological features and outcome of choriocarcinoma : retrospective study from a tertiary cancer center in India, Joydip Ghosh, Sayantika De, Deepak Dabkara, Joydip Bhaumik **Oct 2021** , CRST
- High sensitive CRP as a prognostic and predictive marker in metastatic NSCLC, A prospective single center study . Debopriya Modal, Sandip Ganguly, Joydip Ghsh, Somnath Roy, Deepak Dabkara, Reena Nair, Bivas Biswas. **June 2022**, JCO

Poster presentation in International meetings :

ESMO ASIA

ASCO GU Symposium

Phase III / Phase IV Clinical Trial :

- **Principal Investigator** for phase III Multi-centric randomized study of oral LDK378 Versus standard chemotherapy in previously untreated adult patients with ALK rearranged, stage IIIB / stage IV non squamous non small cell lung cancer (CLDK378A2301), sponsored by Novartis
- **Principal investigator** of Phase IV study of Pertuzumab-Trastuzumab-Docetaxel in metastatic Her 2 +ve breast cancer, - sponsored by Roche
- **PI** - Osimertinib phase IV study in lung carcinoma - AstraZeneca
- **PI** - Phase IV Enzalutamide study on metastatic prostate cancer - sponsored by Astellas
- **PI** for lung cancer adjuvant study - Canakinumab in resected lung cancer – by Novartis
- **PI** : A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
- **PI**: “A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-

Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer”

- **PI** : A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- **PI** : A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)
- **Co I** : An open level, Single arm, Multicenter, Safety study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non Urothelial Carcinoma of the Urinary Tract
- **CO I** : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant / Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
- **Co I** : A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer(TNBC)
- **Co I** : A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)
- **Co I** in lung cancer concordance study - tissue and plasma EGFR mutation study - sponsored by AstraZanecea
- **Co I** in CBKM phase II multi centric, randomized controlled study in recurrent head and neck cancer, sponsored by Novartis
- **Co I** in an open label single arm multicenter safety study of atezolizumab in locally advanced or metastatic urothelial or non urothelial carcinoma of urinary tract – sponsored by Roche
- **Co I** in PARACHUTE : Pazopanib real world assessment of clinical effectiveness and safety in pts who have undergone treatment in different settings in advanced renal cell carcinoma, a prospective non interventional study – by Novartis

- **Co I** in CA – 170 – 201 (ASIAD) study – immunotherapy in solid tumors and hodgkins lymphoma in MSI high patients – phase II study

Invited speaker : Invited as speaker, moderator and panelist in many National meetings
Moderator for session on ADT and cardio-toxicity in Prostate Cancer, Asian cardio oncology society, conference series , 1 Sept 2022

Achievements / Awards

- Observership for 1 month in Taussig Cancer Centre, **Cleveland Clinic Ohio** from 16 Sept to 14 Oct 2017
- **International travel grant** from ESMO ASIA, Singapore in Dec 2015
- Successfully completed the **Certificate Course in Essentials of Palliative Care**, organized by Indian association of Palliative Care, August 2008

Reviewer / Journal editor

- Ex Zonal editor for Indian Journal of Medical and Pediatric oncology
- Reviewer for IJMPO, CRST

Teaching experience : Recognized as a **teacher for DNB (Medical Oncology) Superspeciality program**